Formation Channels for Population III Stars at Cosmic Dawn

We present a study of the co-evolution of a population of primordial star-forming minihalos at Cosmic Dawn. In this study, we highlight the influence of individual Population III stars on the ability of nearby minihalos to form sufficient molecular hydrogen to undergo star formation of their own. In the absence of radiation, we find the minimum halo mass required to bring about collapse and star formation to be 10^5 Msun, which then increases to 10^6 Msun after two stars have formed. We find an inverse relationship between the mass of a halo and the time required for it to recover its molecular gas after being disrupted by radiation from a nearby star. We also take advantage of the extremely high resolution to investigate the effects of major and minor mergers on the gas content of star-forming minihalos. Contrary to previous claims of fallback of supernova ejecta, we find that minihalos evacuated after hosting Pop III stars primarily recover gas through mergers with undisturbed halos. We identify an intriguing type of major merger between recently evacuated halos and gas-rich ones, finding that these "dry" mergers accelerate star formation instead of suppressing it like their low redshift counterparts. We attribute this to the gas-poor nature of one of the merging halos resulting in no significant rise in temperature or turbulence and instead inducing a rapid increase in central density and hydrostatic pressure. This constitutes a novel formation pathway for Pop III stars and establishes major mergers as potentially the primary source of gas, thus redefining the role of major mergers at this epoch.Comment: 14 pages, 12 figures, submitted to MNRA

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation